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Available online 18 January 2017Loss or mutation of the tumour suppressor Merlin predisposes individuals to develop multiple nervous system
tumours, including schwannomas andmeningiomas, sporadically or as part of the autosomal dominant inherited
condition Neurofibromatosis 2 (NF2). These tumours display largely low grade features but their presence can
lead to significant morbidity. Surgery and radiotherapy remain the only treatment options despite years of re-
search, therefore an effective therapeutic is required.
Unbiased omics studies have become pivotal in the identification of differentially expressed genes and proteins
that may act as drug targets or biomarkers. Here we analysed the proteome and phospho-proteome of these ge-
netically defined tumours using primary human tumour cells to identify upregulated/activated proteins and/or
pathways.We identified over 2000 proteins in comparative experiments betweenMerlin-deficient schwannoma
and meningioma compared to human Schwann and meningeal cells respectively. Using functional enrichment
analysis we highlighted several dysregulated pathways and Gene Ontology terms.We identified several proteins
and phospho-proteins that are more highly expressed in tumours compared to controls. Among proteins jointly
dysregulated in both tumourswe focused in particular on PDZ and LIMdomain protein 2 (PDLIM2) and validated
its overexpression in several tumour samples, while not detecting it in normal cells. We showed that shRNAme-
diated knockdown of PDLIM2 in both primary meningioma and schwannoma leads to significant reductions in
cellular proliferation.
To our knowledge, this is the first comprehensive assessment of the NF2-related meningioma and schwannoma
proteome and phospho-proteome. Taken together, our data highlight several commonly deregulated factors, and
indicate that PDLIM2 may represent a novel, common target for meningioma and schwannoma.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Meningioma
Schwannoma
NF2
Merlin
Proteome
Phospho-proteome1. Introduction
Neurofibromin 2 (Merlin, NF2) is a tumour suppressor protein
expressed during embryonic development and thereafter (Gronholm et
al., 2005). In adults, significant levels of expression are found in Schwann
and meningeal cells, nerve and lens (Claudio et al., 1997; Sakuda et al.,
1996; Scherer and Gutmann, 1996). Mutations in the encoding gene
(NF2) lead to formation of schwannomas and meningiomas, and less
often of ependymomas and retinal astrocytic hamartomas (Hanemann,
2008; Martin et al., 2010; Rouleau et al., 1993). These tumours originateth Science Park, Research Way,
O. Hanemann).
. This is an open access article undersporadically or as part of the genetic condition Neurofibromatosis type 2
(NF2) (Hanemann, 2008). They are largely unresponsive to classic che-
motherapeutic agents, leaving surgery and radiotherapy as the only re-
maining treatment options which can leave the patient with mild to
severemorbidity (Hanemann, 2008). Additionally, NF2 patients often de-
velop multiple tumours simultaneously (Hanemann, 2008), strengthen-
ing the need for effective systemic therapeutic options. Loss of Merlin
has also been related to a variety of other cancers, including glioblasto-
mas, malignant mesotheliomas and thyroid carcinomas, highlighting its
role as tumour suppressor (Garcia-Rendueles et al., 2015; Guerrero et
al., 2015; Lee et al., 2016; Morrow et al., 2016; Sheikh et al., 2004).
Merlin shares structural similarity with the Ezrin/Radixin/Moesin
(ERM) family of proteins that link the cytoskeleton with components
of the cell membrane (Bretscher et al., 2000; McClatchey, 2003;
McClatchey and Giovannini, 2005). Although Merlin lacks the C-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ERM family, it can localize to the cortical cytoskeleton and interact di-
rectly with the actin-binding protein α-catenin (Gladden et al., 2010).
At sites of cell-cell contact Merlin acts as tumour suppressor controlling
cadherin-mediated contact-dependent inhibition of proliferation and
adherens junction formation (Flaiz et al., 2008; Lallemand et al.,
2003). Several receptor tyrosine kinases (RTKs) have been found to be
Merlin-dependent (Curto et al., 2007; Lallemand et al., 2009).
Our group and others showed overexpression and reduced degradation
of the platelet-derived growth factor receptor β (PDGFRβ) in
schwannoma compared to normal Schwann cells which, together with
the loss of Merlin, leads to increased cellular proliferation and aberrant
activation of the MAPK and PI3K signalling pathways (Ammoun et al.,
2008; Fraenzer et al., 2003). RTKs are found to be linked to Merlin and
thus the cytoskeleton via the PDZ domain–containing adapter NHERF-
1 (Na+/H+ exchanger regulatory factor) (Maudsley et al., 2000;
Weinman et al., 2000). Merlin loss further contributes to tumorigenesis
via the activation of a number of other pathways including the Hippo,
Ras and Wnt/β-catenin (Li et al., 2014; Mohler et al., 1999; Zhao et al.,
2010, 2011). Merlin activity is also in the nucleus, where it binds to
the E3 ubiquitin ligase CRL4 (DCAF1) suppressing its activity. Depletion
of DCAF1 in Merlin-deficient schwannoma cells was sufficient to block
proliferation (Cooper et al., 2011).
Unbiased genomic studies have been performed aiming to identify
novel differentially-expressed genes in schwannomas and meningio-
mas (Fevre-Montange et al., 2009; Hanemann et al., 2006;
Torres-Martin et al., 2013a,b, 2014; Wang et al., 2012) as well as novel
driver mutations, exclusive of NF2 (Clark et al., 2013).
Mass spectrometry (MS) is a powerful, high-throughput technique
to identify thousands of proteins aberrantly expressed and regulated.
Recently Sharma and colleagues performed comparative proteomic
analysis on different grades of meningiomas to investigate alterations
in the meningioma tissue and in the human serum of meningioma pa-
tients compared to normal brain tissue. They identified several
deregulated proteins including transgelin-2 and caveolin in tissue,
plus apoliopoproteins A and E in serum (Sharma et al., 2014, 2015).
Here we analysed by label free quantitative proteomics both the pro-
teomeandphospho-proteomeofmeningiomaand schwannomaprimary
tumour cells. By analysing proteomes and phospho-proteomes together,
we identify overexpressed proteins in tumour cells and regulatory signal-
ling pathways that may be ‘switched off’with therapeutic intervention.
We also compared protein abundances in primary Merlin-deficient
human meningioma cells against human meningeal cells, and primary
human schwannoma cells against primary human Schwann cells. We
identified numerous novel upregulated and downregulated proteins
and phospho-proteins, performed Gene Ontology (GO) mapping and
functional enrichment analyses for GO and pathway terms. We identi-
fied proteins common to both Merlin-deficient tumour types. Several
of the upregulated proteins contained either a PDZ/LIM domain, or
both. These proteins have been shown to have awide range of biological
functions including roles in cell signalling (Te Velthuis et al., 2007). We
found PDZ and LIM domain protein 2 (PDLIM2/ mystique/SLIM) com-
monly upregulated in both tumour types compared to the normal con-
trols. Previous experiments on PDLIM2 suggested a role in cytoskeletal
organization as it was co-immunoprecipitated together with alpha-
actinin-1, alpha-actinin-4, filamin A, and myosin heavy polypeptide 9
in rat corneal epithelial cells (Loughran et al., 2005a; Torrado et al.,
2004). PDLIM2 was also identified at the nuclear level exerting tumour
suppressive functions by terminating NF-κB activation during inflam-
mation (Tanaka et al., 2007) and in breast cancer (Qu et al., 2010).
PDLIM2 overexpression was found in metastatic cancer cells
(Loughran et al., 2005b) and androgen-independent prostate cancer
cell lines (Kang et al., 2016). Using our primary human cultures we per-
formed PDLIM2 silencing in primary human schwannomas and menin-
giomas and observed a statistically significant reduction in cell
proliferation in both tumour types.To our knowledge, this work is the first proteomic study aiming to
decipher common deregulated elements in the proteome and
phospho-proteome of Merlin-deficient schwannomas and meningiomas.
2. Materials and Methods
2.1. Clinical Samples
Meningioma and schwannoma specimens were collected after pa-
tients consented to the study and given a unique MOT identification
number. This study was granted full national ethics approval by the
SouthWest research ethics committee (RECNo: 14/SW/0119; IRAS pro-
ject ID: 153,351) and local research and development approval (Plym-
outh Hospitals NHS Trust: R&D No: 14/P/056 and North Bristol NHS
Trust: R&D No: 3458). Normal human Schwann cells were collected
after ethical approval under the REC number REC6/Q2103/123. The
brain tumour material was obtained from the Imperial brain tumour
bank and this sub-collection is covered by Imperial College Tissue
bank ethics. All meningioma samples used in this study were grade I.
2.2. Cell Culture
Human meningeal cells (HMC) were obtained from Sciencell™ and
maintained in the manufacturer's recommended media at 5% CO2.
Human primary Schwann/schwannoma cells were maintained as de-
scribed previously (Rosenbaum 2000). Ben-Men-1 cells and primary
meningioma cells were routinely grown in DMEM, 10% FBS and
100 U/ml Penicillin/Streptomycin, and were kept at 5% CO2/37 °C.
2.3. Phospho-protein Purification
Phospho-proteinswere isolated from cell lysates using the commer-
cially available phospho-protein purification kit from Qiagen®. The
manufacturers reported an enrichment of over 80% with less than 5%
phosphorylation in the flow-through fraction. Similarly Meimoun et
al. reported an enrichment of 88% using this kit (Meimoun et al.,
2007). The protocol was carried out according to themanufacturer's in-
structions using 2.5mgof startingmaterial. Protein concentrationswere
determined by the BCA protein assay according to the manufacturer's
instructions.
2.4. In-gel Digestion
Cells were lysed in the buffer provided with the phospho-protein
purification kit. 50 μg of protein and corresponding isolated phospho-
protein were separated via SDS-PAGE. Gels were stained with colloidal
coomassie blue stain (Life Technologies) for 3 h at room temperature
(RT). Destaining was performed using MS grade water (Fisher) over-
night at RT. Individual lanes were cut into small 1 mm × 1 mm pieces
before in-gel digestion as described previously (Lasonder et al., 2002).
The protocol was performed as follow per slice: equilibration in 200 μl
of 50 mM ammonium bicarbonate (ABC) for 5 min at 37 °C, destaining
in 200 μl of 50% acetonitrile (ACN)/50% H2O for 5 min at 37 °C then
200 μl of 100% ACN for 5 min at 37 °C. These steps were performed in
triplicate. 200 μl of reduction buffer (10 mM dithiothreitol in ABC)
was added to the gel slices and incubated for 20 min at 56 °C. Slices
were then shrunk using 100% ACN for 5 min at RT and alkylated using
200 μl of alkylation buffer (23.35 mg 2-choloroacetamide, 5 ml 50 mM
ABC) for 20 min at RT in the dark. The gel pieces were incubated with
digestion buffer (12.5 ng/μl trypsin in ABC) overnight at 37 °C. Digested
peptides were extracted by the addition of 2% Trifluoroacetic acid (TFA)
to the digestion buffer incubated for 20min on a shaker at 37 °C. Peptide
solutions were transferred to fresh tubes, and 100 μl of buffer B (80%
ACN, 0.5% acetic acid, 1% TFA)was added to the gel pieces and incubated
for a further 20 min on a shaker at 37 °C. The buffer B solution was then
combined with the solution from the first peptide extraction, and
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until less than 40 μl of sample was left. Samples were then dissolved in
buffer A (0.5% acetic acid, 1% TFA) prior to MS analysis.
2.5. Peptide Purification With Stage Tips
Stage tips were assembled by placing high performance C18 extrac-
tion disks into pipette tips as described (Rappsilber et al., 2003). 50 μl of
methanolwas added to theprepared stage tips and centrifuged until the
whole volume passed through. This was repeated with buffer B (80%
acetonitrile, 0.5% acetic acid) and then twice with buffer A (0.5% acetic
acid). Samples were added to stage tips and centrifuged (1 min;
10,000 ×g at RT). 50 μl of buffer A was then added and centrifuged
until all the volume had passed through. Peptides were eluted by addi-
tion of 20 μl of buffer B and centrifugation. The samples were concen-
trated using a speed vac before resuspension in buffer A to give a final
volume of approximately 25 μl (Rappsilber et al., 2003).
2.6. Liquid Chromatography Tandem Mass Spectrometry
MS was carried out using an Ultimate 3000 UPLC system (Thermo
Fisher, Germany) connected to anOrbitrapVelos Promass spectrometer
(ThermoFisher, Bremen, Germany). The prepared peptideswere loaded
on to a 2 cm Acclaim™ PepMap™ 100 Nano-Trap Column (Thermo
Fisher, Germany) and separated by a 25 cm Acclaim™ PepMap™ 100
Nano LC column (Thermo Fisher, Germany) packed with C18 beads of
3 μmand running a 120min gradient of 95% buffer A/5% buffer B (buffer
A contains 0.5% acetic acid and buffer B contains 0.5% acetic acid in 100%
acetonitrile) to 65% buffer A/35% buffer B and a flow rate of 300 nl/min.
Eluted peptides were electrosprayed into the mass spectrometer at a
spray voltage of 2.5 kV. The Orbitrap instrument performs data acquisi-
tion in a data dependent mode to switch between MS and MS2. The
Orbitrap cell with a resolution of 60,000 acquires a full-scan MS spec-
trum of intact peptides (m/z 350–1500)with an automated gain control
accumulation target value of 1000,0000 ions. In the linear ion trap the
ten most abundant ions are isolated and fragmented by applying colli-
sion induced dissociation using an accumulation target value of
10,000, a capillary temperature of 275 °C, and normalized collision ener-
gy of 30%. A dynamic exclusion of ions previously sequencedwithin 45 s
was applied. Any singly charged ions and unassigned charged states
were excluded from sequencing and a minimum of 10,000 counts was
required for MS2 selection. Dynamic exclusion is a widely used tool in
mass spectrometry data acquisition software enabling more proteins
to be identified and increase proteome coverage (Zhang et al., 2009).
2.7. Protein Identification
Andromeda search engine integrated in MaxQuant version 1.3.05
programme was used to identify the proteins in the Uniprot database
(www.uniprot.org/downloads, November 2015) and supplemented
with sequences of frequently observed contaminants. A mass tolerance
of 6 ppm for the parental peptide and 0.5 Da for fragmentation spectra
and a trypsin specificity allowing up to 2 mis-cleaved sites were
set as the Andromeda search parameters. Fixed modifications of
carboxyamidomethylation of cysteines and variable modifications of
oxidation of methionine, deamidation of glutamine and asparagine
were set. A minimal peptide length of 7 amino acids was set. MaxQuant
performed an internal mass calibration of measured ions and peptide
validation by the target decoy approach as described. Proteins and pep-
tides with a better than 1% false discovery rate (FDR) were accepted if
they had been identified by at least 2 peptides in one of the samples.
Shared peptide sequences (razor peptides) were mapped to proteins
by the principle of maximum parsimony in MaxQuant. Proteins were
quantified by normalized summed peptide intensities computed as
label free quantification (LFQ) values in MaxQuant 1.3.05￼ (Cox etal., 2014) LFQ data was generated in triplicate for all samples. LFQ data
was generated in triplicate for all samples.
2.8. Quantification Analysis
LFQ data generated by Maxquant were processed using Microsoft
Excel and specially developed proteomics software, Perseus (Tyanova
et al., 2016). LFQ values for proteins and phospho-proteins were Log2
transformed and fold change (FC) was calculated based on the equa-
tion: Average Log2 LFQ tumour - Average Log2 LFQ control. Entries
with 0 for LFQ were kept and included in the fold change calculations.
A 2 sample t-test was performed generating p-values for each identified
protein/phospho-protein. The proteins with a p-value b 0.05 were con-
sidered differentially expressed and included in further analysis. Signif-
icantly changed phospho-proteins were compared against respective
protein changes to identify those that are relatively highly upregulated
i.e. displaying a large significant change in phosphorylation and a small-
er increase or a decrease in protein abundance.
2.9. Functional Enrichment Analysis
Functional enrichment analysis was performed using Benjamini-
Hochberg multiple correction testing integrated in to the database for
annotation, visualization and integrated discovery (DAVID) software
(Huang da et al., 2009) for Gene Ontology (GO) annotations and for
KEGG pathways annotations. Functional enrichment analysis compares
coverage of GO and pathway terms from significantly differentially
expressed proteins with coverage of these terms in a defined control
background – in this case the entire human proteome. This allows path-
ways, biological processes, molecular functions and proteins of particu-
lar cellular components to be identified that are proportionally over
represented in the experimental dataset than they are in the back-
ground dataset and calculated as fold enrichment. We accepted
enriched GO and pathway terms with p adjusted b 0.05 and Fold
Enrichment N 2.
The representative steps involved in target identification are pre-
sented in Fig. S1.
2.10. Western Blotting
Cells were lysed in RIPA buffer consisting of (150 mM NaCl, 1% Tri-
ton-X, 0.5% Sodium deoxycholate, 0.1% SDS and 50 mM Tris pH 8.0) be-
fore protein concentration was determined using a colorimetric BCA
protein assay (Pierce), and immunoblotting proceeded as described
previously (Kaempchen et al., 2003). Samples intended for MS mea-
surement were separated using 4–15% gradient pre-cast gels (Bio-
rad). The antibodies used in the study included: Merlin (1:1000),
pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Sig-
naling Technology; PDLIM2 (1:500) from Santa Cruz Biotechnology
and GAPDH (1:50.000) from Millipore.
2.11. Immunofluorescence Microscopy
For immunofluorescence, cells were grown O/N on glass slides. The
following day slides were washed twice with PBS and fixed with 4%
Paraformaldehyde (PFA)/PBS for 10 min. Slides were then washed
twice with PBS and cells were permeabilized with 0.2% Triton X-100/
PBS for 5 min at RT. Slides were washed three times with PBS and
blocked for 1 h in 10% BSA/PBS at RT. Primary antibodies were
diluted in 5% BSA/PBS and incubated O/N at 4 °C. Slides were then
washed thrice in PBS for 5 min each and incubated with secondary
antibodies (1:200, Alexa Fluor®, Life Technologies), nuclear counter-
stained (DAPI, 4 μg/ml) and mounted with ProLong Diamond antifade
mountant (Life Technologies). Confocal microscopy was performed
using a Leica DMI6000B microscope.
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Cultured cells were seeded at 80% confluency before transfection
with lentiviral particles (10 μl/6 well, 2 μl labtek) directed towards
PDLIM2 (Sigma) in the presence of 5 μg/ml polybrene (Santa Cruz bio-
technology). Lentivirus was applied for 24 h, at which point medium
was removed and replaced with normal medium for a further 24 h. Pu-
romycin was then applied to cells at a concentration of 5 μg/ml for cell
selection. Selection took place over 4–5 days, at which point cells were
lysed for Western blot analysis, or fixed and stained for Ki-67 expres-
sion. Five different shRNA clones were tested (sequence clone 1:
CCGGCTCGGAAGTCTTCAAGATGCTCTCGAGAGCATCTTGAAGACTTCCG-
AGTTTTTTG; sequence clone 2: CCGGGCTCTTACATGAGCTAAGTTTC
TCGAGAAACTTAGCTCATGTAAGAGCTTTTTTG; sequence clone 3:
CCGGGAGGACATACACTGAGAGTCACTCGAGTGACTCTCAGTGTATGTCC-
TCTTTTTTG; sequence clone 4: CCGGCCACTGCCTTTGATCAACCTT
CTCGAGAAGGTTGATCAAAGGCAGTGGTTTTTTG; sequence clone 5:
CCGGGAGCTGTACTGTGAGAAGCATCTCGAGATGCTTCTCACA GTACAGC
TCTTTTTTG), cloned into the plasmid pLKO.1-puro. Clone 5 was the
most successful in knocking down PDLIM2.
2.13. λ-Phosphatase Treatment and Cytoplasmic-nuclear Extraction
Cellswere lysed in RIPA buffer containing protease inhibitors but not
phosphatase inhibitors. Protein dephosphorylation was achieved by
treating 20 μg of protein lysate with λ-phosphatase (New England
Biolabs) following the instructions of the supplier. The reaction was
allowed to proceed for 2 h at 30 °C. Non treated sample was incubated
in the same buffer and for the same amount of time at 30 °C but water
was added in place of λ-phosphatase.
To ascertain the cellular location of PDLIM2, a cytoplasmic and nu-
clear extraction assay (Thermo Scientific) was performed. Primary ad-
herent meningioma cells were harvested with trypsin and centrifuged
at 500 g for 5 min. The cell pellet was then washed once in PBS, trans-
ferred to a microcentrifuge tube and centrifuged for 3 min at 500 g. Ice
cold CER I reagent (Cytoplasmic Extraction Reagent, provided with the
kit) was added to the pellet, vortexed vigorously for 15 s and incubated
on ice for 10 min. Ice cold CER II was then added to the tube and
vortexed for 5 s on the highest setting before incubation on ice for
1 min. The tube was then centrifuged for 5 min at 16,000 g and the su-
pernatant immediately transferred to a pre-chilled tube (the cytoplas-
mic fraction). Ice cold NER (Nuclear Extraction Reagent, provided with
kit) was added to the remaining pellet and vortexed for 15 s. After incu-
bation on ice for 40min with rigorous vortexing every 10min, the tube
was centrifuged atmaximum speed for 10min. The supernatant (nucle-
ar fraction) was transferred to a clean tube and both extracts were
stored at−80 °C until analysis byWestern blot. The experimentwas re-
peated in triplicate on three different meningioma cell populations.
Total HDAC1 and GAPDH were included as reference proteins for the
nuclear and cytoplasmic fractions respectively.
3. Results
3.1. Differential Protein and Phospho-protein Expression in Schwannoma
vs. Schwann Cells
Three primary Merlin-deficient schwannoma-derived cell popula-
tions were analysed vs. human primary Schwann cells. Merlin status
was confirmed byWestern blot prior toMS analysis (Fig. 1A). The global
proteome and the isolated phospho-proteomewere measured in paral-
lel to allow an indirect comparison between proteome and phospho-
proteome data, and also to identify both phosphorylated and non-phos-
phorylated potential targets. Over 1559 proteins (Table S1a) (peptides
in Table S1c) and over 2455 phospho-proteins (Table S1b) (peptides
in Table S1d) were identified in primary schwannoma vs. Schwann
cells with a 32% overlap (Fig. S5a). Only 16 proteins in the proteomedataset were found to be significantly upregulated with a Log2FC N 1,
while 93 proteins were downregulated with a Log2FC b−1. A list of
the significant differentially expressed proteins is summarized in
Table S2. The top three upregulated include the fructose-bisphosphate
aldolase C (ALDOC), the proteasome subunit beta type-5 (PSMB5) and
transgelin (TAGLN), the latter identified also in previous studies
(Sharma et al., 2015). All upregulated proteins were grouped based on
protein class and are represented by a pie chart (Fig. 1B). The largest
proportion of upregulated proteins were cytoskeletal (50%). Interest-
ingly, 11 of the 16 upregulated proteins interact with one another, as
identified by string.db (Fig. S3). In the phospho-proteome dataset, 122
were significantly upregulated with a log fold-change over 1 and
101 phospho-proteins were significantly downregulated with a
Log2FC b−1 (Table S3). Among the most upregulated phospho-pro-
teins was the Yorkie homolog (YAP), previously shown to be active in
schwannoma (Li et al., 2014) as well as members associated to the Ras
pathway (Ammoun et al., 2008; Morrison et al., 2007).
In order to identify individual proteins aberrantly regulated that
may be involved in protein signalling and pathway activation, we
analysed the phospho-proteome dataset with respect to whole path-
ways and/or biological processes that are significantly represented
usingDAVID (Huang da et al., 2009). The upregulated phospho-proteins
were mapped to several pathways (Fig. 1C). Among the statistically
enriched pathways (Benjamini-Hochberg Adjusted p b 0.05) represent-
ed by the upregulated proteins were focal adhesion (18%, Fold enrich-
ment (FE) 5), the MAPK pathway (16%, FE 3) and regulation of the
actin cytoskeleton (12%, FE 3), pathways that have previously been
shown to be activated in schwannoma (Ammoun et al., 2014; Schulze
et al., 2002). Among the other deregulated pathways identified were
endocytosis (12%, FE 3), vascular smooth muscle contraction (12%, FE
6), neurotrophin signalling (9%, FE 4), glycolysis/gluconeogenesis (7%,
FE 6). We also performed functional enrichment analysis on the upreg-
ulated phospho-protein dataset to identify the most significant GO
terms (Fig. 1D). RAS protein signal transduction was identified as the
most enrichedbiological process in linewith the role of the Ras pathway
in schwannoma (Ammoun et al., 2008; Morrison et al., 2007). Themost
enriched GO term overall corresponding to upregulated phospho-pro-
teins is ‘AP-2 adaptor complex’, linked to clathrin-mediated endocyto-
sis. Among the downregulated phospho-proteins, there was
significant enrichment of lysosomal proteins (Fig. S3). These are ARSA,
AGA, CTSD, GUSB, PSAP and SMPD1. CTSD, or Cathepsin D, in particular
is associated with caspase-3 induction of cell death and its downregula-
tion may be related to schwannoma cell survival (Pranjol et al., 2015).
In order to identify proteins thatwere highly activatedwewanted to
identify those that displayed a relatively small change in protein abun-
dance relative to phospho-protein expression. The simplest way of
performing this analysis was to plot both datasets against each other
as Log2FC, allowing for fast visual identification of the highly upregulat-
ed phospho-proteins (Fig. 1E). Fold changes of significantly changed
phospho-proteins (p-value b 0.05) are plotted on the y axis, against
their respective protein fold changes (irrespective of p-value). The
most relevant differences were found on the top part of the graph;
among them we found several cytoskeletal-related proteins like
PDLIM2, PDLIM5 and PDLIM7, the regulator of cell polarity Rho-associ-
ated protein kinase 1 (ROCK1), Filamin-B and Vinculin. Numerous
were also involved in vesicular transport like the alpha-soluble NSF at-
tachment protein (NAPA), the Charged Multivascular Body Protein 2B
(CHMP2B) and the Vacuolar Protein Sorting-associated 29 (VPS29).3.2. Differential Protein and Phospho-protein Expression inMeningioma vs.
Meningeal Cells
Three primary human meningioma-derived cell populations (MN)
and the meningioma cell line Ben Men-1 (Puttmann et al., 2005),
were analysed against Human Meningeal Cells (HMC) as normal
Fig. 1. Functional comparative analysis of schwannoma vs. normal Schwann cells. (A) Western blot showing Merlin expression in normal human Schwann cells and loss of Merlin
expression in schwannomas. (B) Pie chart, created using PANTHER.db, showing the upregulated proteins grouped based on protein class. About 50% of the total upregulated proteins
in schwannomas were cytoskeletal. (C) Pie chart showing the upregulated phospho-proteins submitted for functional enrichment analysis using DAVID, the figure highlights a number
of activated pathways in schwannoma cells but not in normal Schwann cells. Focal adhesion and MAPK signalling were the most enriched (18% and 16% respectively). (D) Most
significantly enriched GO terms in the protein classes ‘molecular function’ (green), ‘cellular component’ (blue) and ‘biological process’ (red). As cellular component, the AP-2 adaptor
complex was found highly enriched (about 80%) as well as clathrin-mediated endocytosis (nearly 70% and 50%) (E) Significantly changed phospho-proteins in schwannoma cells vs.
phospho-proteins in normal Schwann cells plotted against their respective protein and phospho-protein amounts. Data were plotted as a Log2FC LFQ tumour/normal.
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prior MS (Fig. 2A).
In the comparison between grade I meningioma primary cells vs.
HMC, 2582 proteins were identified (Table S4a) (peptides in Table
S4c), and after phospho-protein enrichment, we identified 2505
phospho-proteins (Table S4b) (peptides in Table S4d)with a 6% overlap
(Fig. S5b). 186 proteins were upregulated (Log2FC N1) and 494 were
downregulated (Log2FC b−1) (Table S5). Of the identified phosphopro-
teins, 478 were significantly changed between the two cell types; 35
proteins were upregulated (Log2FC N1) and 443 were downregulated
(Log2FC b−1) (Table S6). Due to the relatively low number of signifi-
cantly changed phosphoproteins (35), it was not feasible to detect sta-
tistically significant enriched GO and pathway terms by functional
enrichment analysis in DAVID. We also tested the benign meningioma
cell line and compared Ben Men-1 cells vs. HMC, grown and processed
in triplicate separately and saw a 39% overlap between identified pro-
teins and phosphoproteins (Fig. S5c). In this analysis 3129 proteins
were identified (Table S7a) (peptides in Table S7c), 176 were signifi-
cantly upregulated (Log2FC N1), and 232 were significantly downregu-
lated (Log2FC b−1) (Table S8). Among themost upregulated we found
the tumour necrosis factor receptor superfamily member 10D
(TNFRSF10D), and few integrins (ITGB3, ITGA8, ITGA4, ITGA1). The up-
regulated proteins were grouped based on protein class as before; a
large number of them were nucleic acid binding (29%), cytoskeletal
(17%) or receptor proteins (14%) (Fig. 2B). GO enrichment analysis ofupregulated proteins in the proteome dataset identified terms relating
largely to ECM interaction, collagen and integrin mediated signalling
(Fig. S4).
After phospho-enrichment we identified 2770 proteins (Table S7b)
(peptides in Table S7d) and a total of 240 phospho-proteins were
found significantly upregulated,whilst 195were significantly downreg-
ulated (p b 0.05, Log2FC N 1/b−1, Table S9). The upregulated phospho-
proteins were submitted for functional enrichment analysis using
DAVID. The top enriched pathways were spliceosome (25%), ribosome
(13%) and cell cycle (13%) (Fig. 2C). Proteasome is represented by
11%, meaning a quite significant aberration in the protein degradation
machinery, as well as antigen processing (11%), suggesting a possible
impaired immune response. There was also significant representation
of phospho-proteins involved in non-homologous end joining (NHEJ)
(6%) and nucleotide excision repair (10%). The data therefore also indi-
cates there may be alterations in DNA repair mechanisms. GO enrich-
ment analysis identified significant enrichment of proteasome
activator complex (~80 fold) and proteasome activator activity (~60
fold), as well as positive regulation of ubiquitin-protein ligase activity,
in line with functional enrichment analysis (Fig. 2D).
Significantly changed phospho-proteins were plotted in a graph
against their respective total protein abundances (Fig. 2E). Among
the most interesting phospho-proteins identified were transgelin-2
(TAGLN2), previously found overexpressed in meningioma
(Sharma et al., 2015); calcyclin binding protein (CACYBP), that can
Fig. 2. Functional comparative analysis of meningioma cells vs. normal HMC. (A) Western blot showing Merlin expression in normal HMC and no Merlin expression in meningioma
tumour-derived cells. (B) Pie chart representing the upregulated proteins, grouped based on protein class (PANTHER.db). The top three upregulated protein classes in meningioma
were related to nucleic acid binding (29%), the cytoskeleton (17%) and membrane receptors (14%). (C) Pie chart presentation of the upregulated phospho-proteins submitted for
functional enrichment analysis using DAVID, the figure highlights a number of activated pathways in meningioma cells but not in normal meningeal cells. (D) Most significantly
enriched GO terms in the protein classes ‘molecular function’ (green), ‘cellular component’ (blue) and ‘biological process’ (red). Among them the proteasome was found the most
enriched cellular component (about 80%) and biological process (nearly 60%). (E) Significantly changed phospho-proteins in Ben Men-1 cells vs. phospho-proteins in normal HMC
plotted against their respective protein and phospho-protein amounts. Data were plotted as a Log2FC LFQ tumour/normal.
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type of cancer (Topolska-Wos et al., 2016); Deltex 3 like E3 ubiquitin
ligase (DTX3L), able to modulate DNA damage responses rendering
cancer cells resistant to certain chemotherapy drugs (Thang et al.,
2015). Interestingly, there were several phospho-proteins identified
as downregulated that are related to organization of the cytoskele-
ton like Junction Plakoglobin (JUP), with a Log2FC =−20.663. Pro-
tein abundance was mostly unaltered indicating that decreased
phosphorylation of JUP in tumour cells is perhaps growth permis-
sive. JUP, also known as γ-catenin is structurally and functionally re-
lated to β-catenin. Phosphorylated β-catenin was also found to be
downregulated in Ben-Men-1 cells.
3.3. Schwannoma and Meningioma Common Phospho-proteins
The amount of crossover between differentially expressed phospho-
proteins in schwannoma vs. Schwann cells and in the Ben Men-1 vs.
HMC datasets was as expected higher than with the primary meningio-
ma cells vs. HMC dataset. In the analysis between significantly changed
phospho-proteins in Ben Men-1 cells compared with those in primary
schwannoma cells, 11 were found commonly upregulated and 4 down-
regulated (Table 1). Thus we used this more informative dataset for
comparison and subsequently verified expression in primarymeningio-
ma tumours. Among the commonly upregulated and activated proteins
in both tumours we consistently find PDLIM2 and Filamin-B again. In
addition, we identified the Epidermal growth factor receptor kinaseSubstrate 8-Like protein 2 (EPS8L2), that was found not highly
expressed in the brain and links growth factor stimulation to cytoskele-
tal reorganization and the Ras/Rac pathway (Offenhauser et al., 2004),
and the Signal Transducer and Activator of Transcription 1 alpha/beta
(STAT1). The subunit beta type 8 and type 7 of the proteasome were
also found commonly up- and downregulated respectively, again indi-
cating proteasome dysregulation. We decided to perform initial valida-
tion studies on PDLIM2. This candidate was prioritised for the following
reasons: 1. clear abnormalities in the cytoskeleton of these tumour cells
(Flaiz et al., 2007; James et al., 2008); 2. we identified several upregulat-
ed proteins containing either a PDZ/LIM domain or both; 3. PDLIM2 acts
both as an adaptor protein at the cytoskeletal level (Torrado et al., 2004)
and an E3 ubiquitin ligase into the nucleus (Tanaka et al., 2007); previ-
ous studies identified CRL4(DCAF1), an E3 ubiquitin ligase important in
schwannoma formation and related toMerlin (Li and Giancotti, 2010; Li
et al., 2010), indicating that possibly the regulation of E3 ubiquitin li-
gases is pivotal in the pathogenesis of Merlin-deficient tumours; 4)
PDLIM2 was also identified in primary meningioma with a log2 FC of
2.6 compared with HMC.
3.4. PDLIM2 Is Overexpressed in Both Schwannomas and Meningiomas
We analysed six schwannomas compared with normal human
Schwann cells by Western blot. The protein was found overexpressed
in four out of the six schwannomas compared to the normal Schwann
cell examined (Schwann-0615) (Fig. 3A). A similar analysis was
Table 1
Phospho-proteins commonly and significantly up- or downregulated in Ben Men-1 and
primary schwannoma cells (p b 0.05).
Gene
symbol Protein name
Log2FC
meningioma
Log2FC
schwannoma
CORO1C Coronin-1C 2.60 1.45
CTPS CTP synthase 1 1.23 3.70
CUTA Protein CutA 1.44 1.50
EPS8L2 Epidermal growth factor receptor kinase
substrate 8-like protein 2
3.36 24.27
FLNB Filamin-B 1.22 24.49
HSPA1A Heat shock 70 kDa protein 1A/1B 1.21 3.23
PDE1C Calcium/calmodulin-dependent
3,5-cyclic nucleotide phosphodiesterase
1C
3.16 1.36
PDLIM2 PDZ and LIM domain protein 2 3.94 24.53
PSMB8 Proteasome subunit beta type-8 1.40 1.29
STAT1 Signal transducer and activator of
transcription 1-alpha/beta
4.57 26.24
TCEB2 Transcription elongation factor B
polypeptide 2
1.01 1.02
MAP1A Microtubule-associated protein 1A −19.89 −1.00
PACSIN2 Protein kinase C and casein kinase
substrate in neurons protein 2
−2.11 −1.19
PSMB7 Proteasome subunit beta type-7 −1.17 −1.32
UFL1 E3 UFM1-protein ligase 1 −1.14 −1.43
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Ben Men-1 cells and in six tumour-derived primary cells compared to
normal HMC (Fig. 3B). We also tested the level of PDLIM2 expression
in tumour lysates compared to normal meninges (Fig. 3C). In all cases
PDLIM2 was found overexpressed compared to normal cells or tissue.
3.5. PDLIM2KnockdownHighlyDecreases Cellular Proliferation ofMeningi-
oma and Schwannoma Cells
To investigate the functional relevance of PDLIM2 expression in
schwannoma and meningioma we silenced PDLIM2 in three primary
schwannomas and three primary meningiomas using shRNA lentiviral
particles. PDLIM2 expression was significantly knocked down in
schwannomas cells as confirmed by Western blot (Fig. 3D); this led to
a significant reduction in ki-67 positive cells (p b 0.001), reflecting a
substantial reduction in proliferation in response to the knockdown
(Fig. 3F).
The samewas repeated onmeningioma cells and again we observed
a reduction of protein expression after silencing (Fig. 3E) leading to a
significant decrease in cellular proliferation asmeasured by a ki-67 pro-
liferation assay (Fig. 3G). Altogether these data strongly suggest that
PDLIM2 is involved in cellular proliferation in both schwannomas and
meningiomas.
3.6. PDLIM2 Can Be Phosphoprylated and Localises Into the Nucleus of
Schwannoma and Meningioma Cells
Quantitative proteomic analysis showed a statistically significant in-
crease of PDLIM2 in Ben Men-1 cells compared to HMC after phospho-
protein enrichment (Fig. 4A), suggesting a possible phosphorylated
state of the protein. Unfortunately there are no specific phospho-anti-
bodies commercially available for pPDLIM2, so we performed an in
vitro dephosphorylation assay using lambda phosphatase. The shift of
the PDLIM2 immunoreactive band after Western blot analysis indeed
confirmed the phosphorylation on PDLIM2 (Fig. 4B).
PDLIM2 was previously reported to act as a cytoplasmic protein
(Torrado et al., 2004) and also as a nuclear protein (Tanaka et al.,
2007), exhibiting different functions. To study the localization of
PDLIM2 in our cellular models we performed cytoplasmic and nuclear
protein extraction and examined by Western blot. PDLIM2 was found
to localize largely into the nucleus (Fig. 4C) suggesting a possible func-
tion as E3 ubiquitin ligase as previously reported (Tanaka et al., 2007).We also performed immunofluorescent staining to further determine
PDLIM2 localization and identified it both in the cytoplasm and the nu-
cleus of BenMen-1 and primary meningioma cells (Fig. 4D and E).
4. Discussion
The aim of this study was to decipher the proteome and phospho-
proteome of Merlin-deficient schwannomas and meningiomas relative
to normal controls. Prior to this study, there was only one comparative
analysis between meningioma and schwannoma at the genomic level
reported in the literature (Torres-Martin et al., 2013b, 2014).
We first analysed proteome andphospho-proteome of schwannoma
and meningioma separately, and compared them to their normal con-
trols in order to identify proteins and phospho-proteins significantly
differentially expressed in the two tumour types. Then, we merged
the two sets of candidates identifying the common dysregulated pro-
teins because in NF2 patients these tumours frequently occur together
and need treatment.
Our proteomic analysis was highly informative and revealed many
proteins of potential interest in each dataset. However, despite the
vast amount of information provided by this study there are also some
limitations that have to be considered. Firstly, this research approach
provides a general overview about dysregulated proteins and path-
ways; however, it is impossible to detect the whole proteome as non-
abundant proteins cannot reach the level of detection. Secondly,
phosphoproteomic studies require a large amount of starting material
prior phospho-enrichment; schwannoma and especially human prima-
ry meningioma cells grow at slow rate for a limited number of passages
(b7) making extremely difficult to obtain the required amount of pro-
teins. Like every enrichment technique, there are possible false-posi-
tives in the dataset and additional validation experiments are needed.
The slow proliferation rate of our primary cells likely explain the re-
duced dataset obtained from the analysis of primary meningiomas
which were cultured without the addition of external growth factors
to avoid artificial manipulation of the protein signalling.
While proteome of whole tumour biopsies compared to normalme-
ninges would provide information about environmental signals, here
we decided to conduct the study on primary tumour cells and an
established meningioma cell line, on which it was possible to perform
subsequent functional validation. Using pure tumour cell populations
instead of tissue also makes the comparison between tumours
more meaningful as different tissue would vary in the tumour
microenvironment.
In schwannomas, by functional enrichment analysis, we identified
several factors related to the cytoskeleton and its regulation, in line
with the pivotal role of Merlin as cytoskeletal regulator (Gladden et
al., 2010; Johnson et al., 2002; Lallemand et al., 2003; McClatchey and
Giovannini, 2005). MAPK signalling was also found enriched, in agree-
ment with previous studies (Ammoun et al., 2008; Fraenzer et al.,
2003). Endocytosis, possibly clathrin-mediated, was listed among the
upregulated pathways and cellular components in schwannoma, as
well as the AP-2 adaptor complex required to internalize cargo in
clathrin-mediated endocytosis (McMahon and Boucrot, 2011). This is
in keeping with previous data in flies that showed Merlin is important
for controlling membrane protein turnover in part by regulating endo-
cytosis (Maitra et al., 2006). When the proteome and phospho-prote-
ome were compared in order to identify highly activated proteins, we
identified several cytoskeletal proteins like PDLIM2, Filamin B, Vinculin
and the kinase ROCK1, a key regulator of the actin cytoskeleton and cell
polarity, and previously associated with the ERM family (Hebert et al.,
2008). Again, we recognized proteins related to endocytosis and vesicle
transport like PACSIN3, NAPA, CHMP2B and VPS29.
As opposed to schwannomas, other drivermutations have been iden-
tified in meningioma, but those are mutually exclusive of Merlin (Clark
et al., 2013). In order to keep the genetic background consistent with
schwannoma, we analysed only Merlin-deficient WHO grade I
Fig. 3. PDLIM2 overexpressed in schwannomas and meningiomas is linked to increased proliferation of tumour cells. (A) Western blot analysis of PDLIM2 expression in primary
schwannoma cells compared to primary human Schwann cell. (B–C) Western blot analysis of PDLIM2 expression in Ben Men-1 and primary meningioma cells compared to HMC (B),
and meningioma tumour specimens compared to normal human meninges (C). (D) PDLIM2 shRNA-mediated knockdown in three primary schwannomas, confirmed by the absence
of immunoreactive band in Western blot analysis compared to the sh-scramble control. The samples analysed were; (1) NF1: NF1115 (Fig. 3A), Merlin-positive and pMerlin-positive,
NF0116; (2) NF2: NF0116, Merlin-positive and pMerlin faint band (data not shown); (3) NF3: NF0216, Merlin-negative and pMerlin-negative (data not shown). (E) PDLIM2 shRNA-
mediated knockdown in three primary meningioma cells, confirmed by the reduction of intensity of the immunoreactive band detected by Western blot analysis compared to the sh-
Scramble control. The samples analysed were; (1) MN1: MN026, Merlin-negative and pMerlin-negative (data not shown), (2) MN2: MN028, and (3) MN3: MN031, both Merlin-
negative and pMerlin-negative (Fig. 3B). (F) Ki-67 immunofluorescent staining (green) of the three schwannoma cell populations after PDLIM2 shRNA knockdown compared to sh-
Scramble control. On the left side the histogram showing the highly statistically significant (***, p b 0.001) reduced proliferation in PDLIM2 knockdown cells. (G) Ki-67
immunofluorescent staining (green) of the three primary meningioma cells after PDLIM2 shRNA knockdown compared to sh-Scramble control. On the left side the histogram showing
the statistically significant (*, p b 0.05) reduced proliferation in PDLIM2 knockdown cells. Nuclei are stained with DAPI (Blue). Micrographs are taken at 20× magnification. SC-
Scramble; KD-knockdown.
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ningiomadatasets identifiedpathways thatmight be of particular impor-
tance; among them we found proteasome activation to be a recurring
theme throughout, highlighting it as an important target inmeningioma.
A 2014 study looking at the proteasome inhibitor bortezomib showed
that itwas effective in sensitizingmeningioma cells to TRAIL-induced ap-
optosis (Koschny et al., 2014). Further, the proteasome inhibitor MG132
was also found to increase levels of N-cadherin in schwannoma cells,
which in turn decreased proliferation (Zhou et al., 2011). Our data and
previous reports thus suggest proteasome inhibition as a potential ther-
apy, either alone or in combination with drugs targeting other relevant
pathways. The phosphorylated protein with the largest fold change in
primary meningioma cells was TGM2, or transglutaminase 2. The ex-
pression of this protein has been previously studied in meningioma
and was found to be highly upregulated and suggested as a therapeutic
target. The authors also showed that loss of the NF2 gene was associated
with high expression of TGM2 (Huang et al., 2014). We also found
TAGLN2 as upregulated in meningioma cells, in keeping with previous
proteomic studies on meningioma (Sharma et al., 2015). It is similar in
its function to transgelin (TAGLN), which we identified as highly
expressed in schwannoma. The transgelins are a family of proteins ableto influence a diverse range of cellular processes, including proliferation,
migration and apoptosis (Dvorakova et al., 2014). The study by Sharma
et al. used a similar proteomic approach to identify potential therapeutic
targets usingmeningioma tissue (compared to normal brain) as opposed
to cells. Therewere 12 proteins significantly upregulated and common to
both datasets including the LIM domain containing protein FHL1,
drebrin, fibronectin and translationally controlled tumour protein
(TCTP), all linked with structural regulation.
We also identified possible alterations in DNA repair mechanisms,
consistently with previous results showing chromosome instability
and defects in the mitotic apparatus in meningioma (van Tilborg et al.,
2005), in particular in the NF2-mutated (Goutagny et al., 2010). Studies
by Yang et al. (2012) showed that the tumour suppressor CHEK2 on
chromosome 22q is often deleted together with Merlin, thus impairing
DNA repair mechanisms and increasing chromosomal instability inme-
ningiomas (Yang et al., 2012).
BenMen-1 cells, which have a knownNF2mutation, have been used
as a WHO grade I meningioma cell line model and compared to HMC,
bearing in mind possible modifications due to immortalization
(Puttmann et al., 2005), however helping the study by being an homo-
geneous population of cells. The comparison between Ben Men-1 and
Fig. 4. PDLIM2 acts as phosphoprotein and localises into the nucleus. (A) Histogram showing PDLIM2 MS quantification as Log2 LFQ value in Ben Men-1 (BM) cells vs. HMC after
phosphoenrichment. Phosphorylated PDLIM2 was statistically significantly enriched in Ben Men-1 cells (**, p b 0.012) compared to HMC. (B) Western blot analysis confirming the
phosphorylated status of PDLIM2 in Ben Men-1 cells. Lambda phosphatase treatment (λ-Ph) induced indeed a shift in PDLIM2 immunoreactive band compared to non-treated (NT)
control. (C) Representative Western blot showing PDLIM2 localization after nuclear and cytoplasmic protein fractionation. Total HDAC1 and GAPDH are shown as reference protein for
the nuclear and cytoplasmic fraction respectively. (D) Confocal microscopy (Z-stacks) of PDLIM2 (red) in Ben Men-1 cells and in primary meningioma cells (MN028, MN033, MN036)
(E). Nuclei were stained with DAPI (blue).
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mon upregulated proteins. Among them we identified the epidermal
growth factor receptor kinase substrate 8-like protein 2 (EPS8L2), part
of the EPS family of proteins related to actin cytoskeleton reorganization
under growth factors stimulation (Offenhauser et al., 2004); the cyto-
skeletal protein Filamin-B (FLNB); and the signal transducer and activa-
tor of transcription 1-alpha/beta (STAT1), part of the JAK/STAT1
activated in response to interferon and previously found expressed in
meningiomas (Magrassi et al., 1999), currently under validation.
Here we decided to further analyse PDLIM2 for several reasons; we
identified several PDZ/LIM domains proteins throughout the study, in-
dicating a possibly important role of this family of proteins in Merlin-
deficient tumours. PDLIM2 was first described in 2004 as an adaptor
protein linking other proteins to the cytoskeleton (Torrado et al.,
2004), so its dysregulation inMerlin-deficient tumours appeared highly
plausible. Since, it has been found to have a number of different roles
and has been particularly well studied in breast cancer where it has
been identified as a driver of tumour progression and invasion (Deevi
et al., 2014; Loughran et al., 2005a). In 2007, for the first time PDLIM2
was shown to possess nuclear ubiquitin E3 ligase activity negativelyregulating NF-kappaB by targeting the p65 subunit during inflamma-
tion (Tanaka et al., 2007). Previous studies already identified another
E3 ubiquitin ligase, CRL4(DCAF1), involved in the formation of Merlin-
deficient tumours (Cooper et al., 2011; Li et al., 2010). Finally, the dys-
regulated ubiquitin ligase activity, together with the dysregulated
proteasomal activity found in meningiomas in our study, can suggest
novel therapeutic strategies.
We first confirmed PDLIM2 overexpression in primary meningioma
and schwannoma samples and showed that it is not expressed in HMC
or normal meningeal tissue and minimally expressed in the Schwann
cell examined. PDLIM2 was significantly knocked down in three prima-
ry meningioma and three primary schwannoma cell populations. This
led to significant reductions in cell proliferation in both cell types.
These results are in line with a previous study which showed how
PDLIM2 suppression leads to decreased proliferation in androgen-inde-
pendent prostate cancer cell lines (Kang et al., 2016). On the other hand,
other studies have identified PDLIM2 as an important tumour suppres-
sor (Sun et al., 2015; Zhao et al., 2016). Interestingly enough, PDLIM5,
that we found highly overexpressed in the schwannoma phospho-pro-
teome, was found overexpressed in gastric cancer cells and its siRNA-
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2015), highlighting a possible common role for this family as regulators
of cell proliferation.
Our results showed that PDLIM2 can be phosphorylated. Recently
one proteomic study identified specific phosphoserine sites on
PDLIM2 (Bian et al., 2014); however, no phosphospecific antibodies
are available and the result needs further validation.
Upon subcellular fractionation, PDLIM2 was found to localize into
the nucleus, possibly exploiting E3 ubiquitin ligase activity (Tanaka et
al., 2007). ICC analysis showed it localised to both the nucleus and the
cytoplasm. It may be that PDLIM2 associates with the cytoskeleton
and is thus rendered insoluble during subcellular fractionation, as is
the case with some cytoskeletal proteins e.g. intermediate filaments,
explaining why only nuclear PDLIM2 was detectable via Western blot.
Our overall results indicate that PDLIM2 has both nuclear and cytoplas-
mic functions inmeningioma cells. Additional studieswill be performed
to verify whether the protein acts on p65 even in Merlin-negative me-
ningiomas and schwannomas, and the role of the phosphorylation on
PDLIM2 activity.
In conclusion, we performed a comprehensive analysis of proteome
and phosphoproteome expression in Merlin-deficient schwannomas
and meningiomas, found several dysregulated proteins/pathways in
each dataset and underlying known and novel candidates involved in
the pathogenesis of both tumours. Additionally, we validated the over-
expression of PDLIM2 which was found involved in the proliferation of
bothmeningioma and schwannoma cells, confirming that PDLIM2war-
rants further investigation as a potential common target in Merlin-defi-
cient meningiomas and schwannomas.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2017.01.020.
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